Study identification

EU PAS number

EUPAS1000000808

Study ID

1000000808

Official title and acronym

Comparative effectiveness and safety in patients with prostate cancer who received radical prostatectomy vs. radiotherapy: target trial emulation

DARWIN EU® study

No

Study countries

Estonia
Germany
United Kingdom

Study description

This study aims to compare the effectiveness and safety outcomes in patients with early stage prostate cancer who received radical prostatectomy or radiotherapy using the target trial emulation framework. The study populations of interest include those restricted to the emulated trial eligibility criteria, and the broader population in routine clinical practice.

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

Eng Hooi (Cheryl) Tan 0000-0003-4470-2736

Primary lead investigator
ORCID number:
0000-0003-4470-2736

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Data analysis start date

Actual:

Date of final study report

Planned:
Sources of funding
EU institutional research programme

More details on funding

OPTIMA is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 101034347. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable